fingolimod hydrochloride has been researched along with Hepatocellular Carcinoma in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Alhamad, DW; El-Seedi, HR; Elgendy, SM; Hersi, F; Omar, HA | 1 |
| Chen, X; Li, D; Li, J; Li, Q; Qian, X; Xia, C | 1 |
| An, N; Chen, X; Du, J; He, Q; Qian, M; Yang, B; Ye, S; Yuan, T; Zhang, B; Zhu, H | 1 |
| Hu, W; Ji, AL; Jiang, CP; Lu, X; Qiang, GH; Wang, ZX; Wu, JH; Wu, JY; Zhang, G | 1 |
| Bittman, R; Futerman, AH; Lahiri, S; Laviad, EL; Lu, X; Park, H | 1 |
| Asahara, T; Itamoto, T; Kobayashi, T; Kuroda, S; Miyata, Y; Ogawa, T; Ohdan, H; Tanimoto, Y; Tashiro, H; Ushitora, Y | 1 |
| Berman-Booty, LD; Byrd, JC; Chen, CS; Chou, CC; Hung, JH; Kogure, T; Kulp, SK; Ma, Y; Muthusamy, N; Omar, HA; Patel, T; Terracciano, L; Wang, D | 1 |
| Bittman, R; Fujiwara, Y; Godwin, VI; Liu, J; Osborne, DA; Parrill, AL; Tigyi, G; Valentine, WJ; Van Brocklyn, J | 1 |
| Fan, ST; Geng, W; Li, CX; Ling, CC; Liu, XB; Lo, CM; Ma, YY; Man, K; Ng, KT; Shao, Y | 1 |
| Fan, ST; Ho, JW; Lee, TK; Man, K; Ng, IO; Ng, KT; Sun, CK; Wang, XH; Wong, YC; Xu, R | 1 |
| Fan, ST; Ho, JW; Lee, TK; Man, K; Ng, IO; Ng, KT; Poon, RT; Sun, CK; Wang, XH; Xu, R | 1 |
| Fan, ST; Ho, JW; Lee, TK; Man, K; Poon, RT; Sun, CK | 1 |
| Chu, AC; Fan, ST; Ho, JW; Lee, TK; Man, K; Ng, IO; Ng, KT; Poon, RT; Sun, CK; Sun, HC; Tang, ZY; Wang, XH; Xu, R; Xu, Y | 1 |
| Byrd, JC; Chen, CS; Cheng, AL; Hung, JH; Kulp, SK; Lu, YS; Ma, YH; Muthusamy, N; Wang, DS; Wang, YC | 1 |
14 other study(ies) available for fingolimod hydrochloride and Hepatocellular Carcinoma
| Article | Year |
|---|---|
The inhibition of autophagy by spautin boosts the anticancer activity of fingolimod in multidrug-resistant hepatocellular carcinoma.
Topics: Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Fingolimod Hydrochloride; Humans; Liver Neoplasms | 2022 |
Fabrication of novel ruthenium loaded silk fibroin nanomaterials for fingolimod release improved antitumor efficacy in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Drug Delivery Systems; Fibroins; Fingolimod Hydrochloride; Liver Neoplasms; Nanostructures; Ruthenium; Silk; Tissue Distribution | 2022 |
Fingolimod exerts
Topics: Adaptor Proteins, Signal Transducing; Carcinoma, Hepatocellular; Cell Line, Tumor; Fingolimod Hydrochloride; Humans; Liver Neoplasms; Trans-Activators; Transcription Factors; Transcriptional Coactivator with PDZ-Binding Motif Proteins; YAP-Signaling Proteins | 2022 |
Targeted co-delivery of Beclin 1 siRNA and FTY720 to hepatocellular carcinoma by calcium phosphate nanoparticles for enhanced anticancer efficacy.
Topics: Animals; Apoptosis; Autophagy; Beclin-1; Calcium Phosphates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Delivery Systems; Fingolimod Hydrochloride; Humans; Lipids; Liver Neoplasms; Male; Mice, Nude; Nanoparticles; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2018 |
Ceramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an Acyl-CoA chain length-dependent manner.
Topics: Acyl Coenzyme A; Binding, Competitive; Carcinoma, Hepatocellular; Cell Line, Tumor; Ceramides; Enzyme Inhibitors; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kidney; Liver Neoplasms; Mast Cells; Oxidoreductases; Propylene Glycols; Sphingosine; Tritium | 2009 |
Suppression of hepatocellular carcinoma recurrence after rat liver transplantation by FTY720, a sphingosine-1-phosphate analog.
Topics: Animals; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; Cell Movement; Culture Media; Down-Regulation; Fingolimod Hydrochloride; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Propylene Glycols; Rats; Rats, Inbred BUF; Receptors, Lysosphingolipid; Recurrence; Sphingosine | 2009 |
Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Fingolimod Hydrochloride; Hepatocytes; Humans; Liver Neoplasms; Mice; Mice, Nude; Propylene Glycols; Protein Kinase C-delta; Reactive Oxygen Species; Signal Transduction; Sphingosine; Xenograft Model Antitumor Assays | 2011 |
FTY720 (Gilenya) phosphate selectivity of sphingosine 1-phosphate receptor subtype 1 (S1P1) G protein-coupled receptor requires motifs in intracellular loop 1 and transmembrane domain 2.
Topics: Amino Acid Motifs; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Fingolimod Hydrochloride; HEK293 Cells; Humans; Immunosuppressive Agents; Ligands; Lipids; Mutagenesis; Propylene Glycols; Protein Structure, Tertiary; Rats; Receptors, G-Protein-Coupled; Receptors, Lysosphingolipid; Recombinant Fusion Proteins; Sphingosine | 2011 |
FTY720 suppresses liver tumor metastasis by reducing the population of circulating endothelial progenitor cells.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Fingolimod Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Immunosuppressive Agents; Liver; Liver Neoplasms; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Propylene Glycols; Rats; Reperfusion Injury; Sphingosine; Stem Cells; Time Factors | 2012 |
FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Enzyme Inhibitors; Fingolimod Hydrochloride; G1 Phase; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Immunosuppressive Agents; Liver Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphatidylinositol 3-Kinases; Phosphorylation; Propylene Glycols; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Sphingosine; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2004 |
Significance of the Rac signaling pathway in HCC cell motility: implications for a new therapeutic target.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Fingolimod Hydrochloride; Humans; Liver Neoplasms; MAP Kinase Signaling System; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Propylene Glycols; rac GTP-Binding Proteins; Signal Transduction; Sphingosine | 2005 |
Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents, Hormonal; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Endothelium, Vascular; Fingolimod Hydrochloride; Flow Cytometry; G1 Phase; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microcirculation; Neovascularization, Pathologic; Propylene Glycols; Sphingosine; Transplantation, Heterologous; Umbilical Veins; Wounds and Injuries | 2005 |
FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma.
Topics: Animals; Antigens, CD34; Carcinoma, Hepatocellular; Disease Models, Animal; Down-Regulation; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Liver Neoplasms, Experimental; Mice; Mice, Nude; Microcirculation; Neovascularization, Pathologic; Propylene Glycols; rac GTP-Binding Proteins; Sphingosine; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Wound Healing | 2005 |
FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Enzyme Activation; Fingolimod Hydrochloride; Humans; Liver Neoplasms; Propylene Glycols; Protein Kinase C-delta; Reactive Oxygen Species; Signal Transduction; Sphingosine | 2008 |